PHILADELPHIA, PA – Bruce Schneider, General Medicine Team Leader, Cellular, Tissue, and Gene Therapies, at CDER/FDA will give a featured presentation at the Diabetes Summit to be held in Philadelphia, PA on March 7-8, 2011 by GTCbio. Dr. Schneider will focus on the regulation of new islet beta cell products for treatment of type 1 diabetes. This included allogeneic, embryonic stem cell, and xenogeneic-derived cells.
Also presenting at the Diabetes Summit are prestigious organizations including Sanofi-Aventis, VeroScience LLC, INSERM, Thermalin, Merck, Decision Resources, Metabolic Solutions Development Company, Pfizer, Inspherion, PhysioGenix, Intarcia Therapeutics, Inc., University of Pennsylvania, Abramson Family Cancer Research Institute, Exsulin Corporation, Arisaph Pharmaceuticals, ActivX, Amarex Clinical Research, Children’s Hospital of Philadelphia, Division of Endocrinology & Diabetes, Johnson and Johnson, Macrogenics, Phase Bioscience, Novo-Nordisk Foundation Center for Basic Metabolic Research University of Copenhagen, Merck, Array BioPharma, Comus Bioventures, VIA Pharmaceuticals, Amgen, and Bristol-Myers Squibb.
This Diabetes Summit includes two concurrent tracks: The 4th Diabetes Drug Discovery and Development Conference and the Diabetes Partnering and Deal Making Conference.
For more information, visit www.gtcbio.com.
